Neumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately-Severe Acute Pain

by neumentumadmin | Jan 25, 2023 | Press Releases

NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion NTM-001 has the Potential to Deliver Opioid-Level Pain Relief, Without Analgesic Gaps, and Reduce or Eliminate the Need for Opioids Phase 3...

Neumentum and NEMA Research Inc. Named to Short-List of Citeline Awards for 2021

by neumentumadmin | Sep 20, 2021 | Press Releases

Nominated for Most Successful Early-Phase Research (Morristown, NJ – September 20, 2021) – The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration...

Neumentum to Participate in the UBS Biotechnology Private Company Symposium

by neumentumadmin | Sep 15, 2021 | Press Releases

MORRISTOWN, NJ, September 15, 2021– Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer and co-founder of Neumentum, and Dr. Joseph Pergolizzi,...

Neumentum Presents Latest Data on NTM-006, a Novel Non-Opioid, Non-NSAID Analgesic Drug Candidate, at PAINWeek 2021

by neumentumadmin | Sep 9, 2021 | Press Releases

Data Predicts NTM-006 Efficacy in a Variety of Chronic Pain Conditions MORRISTOWN, NJ, September 9, 2021– Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced data on NTM-006, the company’s...

Neumentum to Participate in Upcoming January Virtual Investor Conferences

by neumentumadmin | Jan 5, 2021 | Press Releases

Neumentum to Participate in Upcoming January Virtual Investor Conferences  MORRISTOWN, NJ, January 5, 2021 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief...

Neumentum to Present New Data for Drug Candidate NTM-001 at the 2020 ASHP Midyear Clinical Meeting and Exhibition

by admin | Dec 8, 2020 | Press Releases

Results from evaluation of novel non-opioid analgesic NTM-001, under development for post-surgical pain, support pathway to potential Phase 3 pivotal trials in 2021 MORRISTOWN, NJ, December 8, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming...